Rekognan, 100 mg/ml 10 ml 10 pcs

Pharmacological group:

Notropic drug

Pharmacotherapeutic group:

Notropic drug

Pharmacological action

Citicoline, as a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: promotes repair of damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms.

In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmission.

In brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, and also helps to reduce the duration of the recovery period.

Cyticoline is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia, citicoline is effective in the treatment of disorders such as impaired memory, lack of initiative, difficulty in performing daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.

Pharmacokinetics

Absorption

Cyticolin is well absorbed when taken orally. Absorption after oral administration is almost complete and bioavailability is approximately the same as after IV administration. After oral administration and parenteral administration the plasma concentration of choline is significantly increased.

Distribution

Cyticoline is largely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and citidine fractions into citidine nucleotides and nucleic acids. Citicoline penetrates the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipids fraction.

Metabolism

In IV and IM administration citicoline is metabolized in the liver to form choline and citidine.

Elimination

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and intestines and about 12% through the exhaled air.

Two phases can be distinguished in the urinary excretion of citicoline: the first phase, lasting about 36 hours, during which the excretion rate decreases rapidly, and the second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled air – the excretion rate drops rapidly after about 15 h and then decreases much more slowly.

Indications

— acute period of ischemic stroke (as part of complex therapy);

— recovery period of ischemic and hemorrhagic strokes;

— traumatic brain injury (TBI), acute (as part of complex therapy) and recovery period;

— cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Pharmacological effect

Clinical and pharmacological group:

Nootropic drug

Pharmacotherapeutic group:

Nootropic drug

Pharmacological action

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also preventing cell death by affecting the mechanisms of apoptosis.

In the acute period of stroke, it reduces the volume of damaged tissue and improves cholinergic transmission.

In case of traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, it helps to reduce the duration of the recovery period.

Citicoline is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia, citicoline is effective in treating disorders such as memory impairment, lack of initiative, and difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Pharmacokinetics

Suction

Citicoline is well absorbed when taken orally. Absorption after oral administration is almost complete, and bioavailability is approximately the same as after intravenous administration. After oral and parenteral administration, the concentration of choline in the blood plasma increases significantly.

Distribution

Citicoline is widely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Citicoline penetrates the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the fraction of structural phospholipids.

Metabolism

With IV and IM administration, citicoline is metabolized in the liver to form choline and cytidine.

Removal

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and through the intestines and about 12% by exhaled air.

The excretion of citicoline in urine can be divided into 2 phases: a first phase, lasting about 36 hours, during which the rate of excretion decreases rapidly, and a second phase, during which the rate of excretion decreases much more slowly. The same is observed in exhaled air – the rate of elimination decreases rapidly after approximately 15 hours, and then decreases much more slowly.

Special instructions

In the solution for oral administration in the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative. With further storage under recommended conditions, the crystals dissolve within several months. The presence of crystals does not affect the quality of the drug.

Active ingredient

Citicoline

Composition

The solution for oral administration is clear, colorless, with a characteristic strawberry odor.

100 ml
citicoline sodium
10.45 g,
which corresponds to the content of citicoline
10 g

Excipients:

sorbitol – 20 g,

glycerol – 5 g,

methyl parahydroxybenzoate – 0.145 mg,

propyl parahydroxybenzoate – 0.025 mg,

potassium sorbate – 0.3 g,

sodium citrate dihydrate – 0.6 g,

sodium saccharinate – 0.02 g,

strawberry flavor FRESA S.1487S – 0.04 g,

citric acid – up to pH 6.0,

purified water – up to 100 ml.

Contraindications

— vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);

– rare hereditary diseases associated with fructose intolerance (for oral administration);

– children and adolescents under 18 years of age (due to the lack of clinical data);

– hypersensitivity to the components of the drug.

There is no information on relative contraindications for oral use of the drug.

Side Effects

Frequency of adverse reactions: very rare (less than 1/10,000) (including isolated cases).

Allergic reactions: rash, itching, anaphylactic shock.

From the nervous system: headache, dizziness, insomnia, agitation, hallucinations. In some cases, the drug can stimulate the parasympathetic system and also temporarily change blood pressure.

From the digestive system: nausea, vomiting, diarrhea, decreased appetite, changes in the activity of liver enzymes.

General reactions: feeling of heat, tremor, shortness of breath, numbness in paralyzed limbs, swelling.

If any of these side effects worsen or any other side effects are noted, the patient should inform the doctor.

Interaction

Citicoline enhances the effects of levodopa.

Should not be administered concomitantly with medicinal products containing meclofenoxate.

Overdose

Given the low toxicity of the drug, cases of overdose have not been described.

Storage conditions

The drug should be stored out of the reach of children, at a temperature of 15° to 25°C.

Shelf life

2 years.

Manufacturer

SAG Manufacturing S.L.U, Spain